论文部分内容阅读
目的:研究急性心肌梗死(AMI)采用阿托伐他汀与替罗非班联合治疗的效果。方法:68例未接受PCI或溶栓治疗的AMI患者根据就诊顺序分为两组:对照组34例患者应用常规治疗,观察组34例在常规治疗的基础上加用阿托伐他汀与替罗非班治疗,对比两组的临床疗效。结果:观察组治疗总有效率为85.29%(29/34),与对照组的73.53%(25/34)比较差异显著(P<0.05);观察组的心血管事件发生率为8.82%(3/34),较对照组的26.47%(9/34)显著降低(P<0.05);两组的不良反应比较差异无统计学意义(P>0.05)。结论:阿托伐他汀联合替罗非班治疗AMI能够提高临床疗效,且副反应较少,具有一定的临床应用价值。
Objective: To study the effect of combination therapy of atorvastatin and tirofiban on acute myocardial infarction (AMI). Methods: Sixty-eight AMI patients who did not receive PCI or thrombolytic therapy were divided into two groups according to the order of treatment: 34 patients in the control group were treated with conventional therapy, 34 patients in the observation group were treated with atorvastatin and tirolol Non-class therapy, compared the clinical efficacy of the two groups. Results: The total effective rate of the observation group was 85.29% (29/34), which was significantly different from that of the control group (73.53%, 25/34) (P <0.05). The incidence of cardiovascular events in the observation group was 8.82% (3) / 34), which was significantly lower than that of the control group (26.47%, 9/34) (P <0.05). There was no significant difference in adverse reactions between the two groups (P> 0.05). Conclusion: The combination of atorvastatin and tirofiban in AMI can improve the clinical curative effect with fewer side effects and has certain clinical value.